? 中國疫苗產業技術創新戰略聯盟第二次會議在京召開_企業動態_新聞中心_中國生物技術股份有限公司

中國疫苗產業技術創新戰略聯盟第二次會議在京召開

2020-05-20 22:49

5月18日晚,國家主席習近平在第七十三屆世界衛生大會視頻會議開幕式上發表題為《團結合作戰勝疫情 共同構建人類衛生健康共同體》的致辭,他在致辭中宣布:中國新冠疫苗研發完成并投入使用后,將作為全球公共產品,為實現疫苗在發展中國家的可及性和可負擔性做出中國貢獻。



為加快做好新冠疫苗的研發保障,加強疫苗領域技術創新和科技合作,5月18日,中國疫苗產業技術創新戰略聯盟第二次會議在京召開(以下簡稱“疫苗聯盟”)。



疫苗聯盟指導單位科技部中國生物技術發展中心孫燕榮副主任和盧姍副處長出席會議,會議特別邀請到國務院聯防聯控機制科研攻關組疫苗研發專班武治印處長到會指導。來自中國疫苗研發、生產、監管和應用等領域的機構,包括政府部門、科研院所、高校、生產企業等共27家理事單位,共60余人以現場加遠程的方式參加了會議。

 

▲疫苗聯盟理事長、中國生物董事長楊曉明

疫苗聯盟理事長、中國生物董事長楊曉明首先代表聯盟致歡迎辭,他指出,隨著新型冠狀病毒感染的爆發和流行,全球公共衛生安全面臨嚴峻挑戰和考驗,進行快速應急響應、成功研制疫苗成為當前及今后一段時間的迫切任務。疫苗是防控傳染病最經濟、最有效的手段,也是進行生物安全防護、維護國家安全的重要手段。目前疫情防控已從應急狀態轉為常態化,當前的首要任務是全力保障人民生命健康安全,全面恢復社會經濟秩序,而疫苗是完成這一任務的根本舉措。中國是世界上為數不多能夠依靠自身能力解決免疫供應和疫苗接種的國家之一,目前能夠應對大部分對人群危害大、傳染性強的傳染性疾病,也初步形成了疫苗應用研究和產業化開發體系,但距離目標還有一定差距。今天,疫苗聯盟的理事單位已從14家增加到27家,是中國疫苗產業發展的中流砥柱。目前,時逢全球抗疫的重大時刻,如何實現疫情防控的終極目標、完成中國疫苗產業的任務和使命、聯合全球同行共同抗擊疫情,早出苗,出好苗,保供應,促應用,是需要共同研討的主題,希望與會專家為推動科技抗疫、加強我國疫苗產業發展以及促進國際聯合抗疫積極建言獻策。


▲科技部中國生物技術發展中心副主任孫燕榮

科技部中國生物技術發展中心副主任孫燕榮在致辭中表示,科技是戰勝新冠疫情最有力的武器,是讓生活回歸正常的有力支撐。她用幾個“一百”談了自己的感受,一是一百年,中國疫苗制品事業已走過百年發展歷程,人們從被動免疫到主動免疫,實現了人均壽命的大幅提升;二是一百天,從疫情爆發至今的一百多天時間里,中國的十幾支科研攻關團隊全力以赴、夜以繼日的研發疫苗,不僅要快,還要好,正因為他們的努力,我們才能在今天有5支研發團隊的疫苗進入到了臨床試驗階段;三是一百人,在這次科研攻關中,我國布局了5條疫苗研發技術路線,12支研發團隊,除此之外,我們還有百位骨干、百位技術人員在努力付出,讓我們看到了走出疫情、戰勝疫情的希望;四是一百項,目前全球有一百多個產品正在研發,我們看到了全球科學家們共同的努力、企業家們無私的奉獻,為全球戰疫貢獻力量;五是一百分,相信我們疫苗事業百年的歷史積累與沉淀,能夠真正為研制出安全有效的疫苗、為全球疫情防控、守護全人類生命健康做出新的貢獻。


▲國務院聯防聯控機制科研攻關組疫苗研發專班武治印處長

國務院聯防聯控機制科研攻關組疫苗研發專班武治印處長在致辭中指出,疫苗是全球對抗新冠疫情的“壓艙石”,目前新冠疫苗研發取得重要進展,感謝所有科研團隊對于新冠疫苗研發付出的努力。但疫苗研發工作絲毫不能放松,各科研團隊應提高戰略布局、著眼未來、協同作戰、加速研發,爭取新冠疫苗的早日上市。

 

▲中國生物副總裁張云濤

中國生物副總裁張云濤介紹了疫苗聯盟成立的情況及聯盟任務、職責,并系統介紹了國內外新冠疫苗研發進展,對新冠疫苗未來發展進行了研判。


現場,比爾及梅琳達·蓋茨基金會疫苗開發小組主任Anita Zaidi博士,帕斯適宜衛生科技組織(PATH)基本藥物副總裁、疫苗創新和可及性中心負責人David Kaslow博士,前英國國家生物制品檢定所(NIBSC)副所長Philip Minor博士,全球疫苗免疫聯盟(GAVI)總裁Seth Berkley博士等也專門錄制了視頻,為會議的舉辦送上寄語,并對中國在此次疫情防控中的表現和貢獻給予肯定。


蓋茨基金會疫苗開發部主任Anita Zaidi博士表示,很高興看到中國在新冠疫苗研發方面作出的重大努力和投入,中國的研究人員已經建立了包含多種疫苗路線的研發管線,這體現了中國公共與私營部門一起應對這一全球巨大挑戰的堅定承諾。Anita Zaidi博士指出,蓋茨基金會支持中國的合作伙伴應對此次大流行病挑戰,會共同開發和部署疫苗、藥物和診斷試劑來為全球提供幫助。


PATH副總裁David Kaslow對中國疫苗創新聯盟的創立表示非常高興,并肯定了中國疫苗研發和生產能力的進步及對全球健康的貢獻。他表示,在與中國的疫苗合作伙伴共事期間,PATH不斷看到中國創新力量釋放出的巨大潛力,看到中國正在開發超過50種針對新冠的候選疫苗,其中一些正在以前所未有的速度推進,希望接下來,中國疫苗企業能夠繼續為全球供應安全有效的疫苗做出重要貢獻。


前NIBSC副所長Philip Minor博士認為中國具有強大的科研能力和強大的疫苗生產能力,開發了大量適用于本國使用的特殊用途的疫苗,例如肝炎疫苗和EV71,這些能力可以在開發新冠疫苗方面得到很好的應用。


GAVI總裁Seth Berkley博士首先對中國在遏制疫情方面取得的成功表示熱烈的祝賀,他指出,如今世界正面臨著100年來最大的公共衛生危機,當前能化解這一危機的最大希望是開發出疫苗。國際合作將是抗擊新冠疫情的關鍵,中國疫苗聯盟的倡議和創新可以為全球衛生安全做出巨大貢獻,GAVI期待著與中國制造商繼續合作。


張云濤代表中國疫苗產業技術創新戰略聯盟向全體疫苗行業同仁宣讀了倡議書。倡議書中強調:面對新冠肺炎疫情的復雜局面,要進一步發揮疫苗企業在抗擊疫情中的作用,更好的履行社會責任,共同推進疫苗科技攻關,做好疫苗研發保障,保證疫苗應用安全,充分發揮疫苗在維護公眾健康、保障國家安全方面的重要作用;要加強疫苗全產業鏈建設,整體提升疫苗產業服務社會的水平和能力;推進疫苗研發國際合作,攜手全球抗疫,彰顯大國擔當,與世界人民共同建設“人類衛生健康共同體”,與世界各國一道攜手應對,早日戰勝這場全球性疫情。


中國食品藥品檢定研究院王軍志院士、NIBSC首席科學家Dr.Javier Martin分別就新冠疫苗研發等問題進行了主題發言。隨后與會人員就如何發揮疫苗聯盟的作用等內容進行了充分研討。最后,楊曉明對討論進行了總結,表示未來將進一步聚焦聯盟任務,突出疫苗的作用。


附疫苗聯盟理事單位:

1、中國生物技術股份有限公司

2、艾棣維欣(蘇州)生物制藥有限公司

3、北京艾美生物疫苗技術集團有限公司

4、北京科興生物制品有限公司

5、北京民海生物科技有限公司

6、重慶智飛生物制品股份有限公司

7、復旦大學8、廣西壯族自治區疾病預防控制中心

9、河南省疾病預防控制中心

10、華蘭生物工程股份有限公司

11、江蘇省疾病預防控制中心

12、軍事醫學研究院生物工程研究所

13、康希諾生物股份公司

14、清華大學

15、廈門大學

16、斯微(上海)生物科技有限公司

17、四川大學

18、蘇州艾博生物科技有限公司

19、云南沃森生物技術股份有限公司

20、長春百克生物科技股份公司

21、中國疾病預防控制中心病毒病預防控制所

22、中國疾病預防控制中心傳染病預防控制所

23、中國疾病預防控制中心免疫規劃中心

24、中國科學院上海巴斯德研究所

25、中國食品藥品檢定研究院

26、中國醫學科學院醫學生物學研究所

27、珠海麗凡達生物技術有限公司


為加速我國疫苗研發水平,促進產業關鍵技術升級和疫苗產品質量提升,加強我國疫苗產業的技術儲備、提高應對新發、突發疫情和疾病防控的能力、促進疫苗產業的健康發展,在科技部的推動支持下,2013年,中國生物作為聯盟依托單位牽頭成立了疫苗產業技術創新戰略聯盟。




Strengthen vaccine protection  

Join hands with the global fight against the epidemic  

They have issued important initiatives!


On the evening of May 18, At the opening ceremony of the 73rd World Health Assembly video conference, President Xi Jinping delivered a speech entitled "Unity and Cooperation to Overcome the Epidemic and Build a Human Health Community", In his speech, he announced whenever the COVID-19 Vaccine finishes its R&D phase and put into use, it will serve as a global public product and make China's contribution to the accessibility and affordability of vaccines in developing countries.


In order to speed up the research and development of COVID-19 Vaccine and strengthen technological innovation and cooperation in the vaccine field, the second meeting of the China Vaccine Industry Technological Innovation Strategic Alliance was held in Beijing on May 18 (hereinafter referred to as the "Vaccine Alliance").


Sun Yanrong, Deputy Director, and Lu Shan, Deputy department Chief of the China National Center for Biotechnology Development of the Ministry of Science and Technology attended the meeting. Wu Zhiyin, director of the Vaccine research and development committee for COVID-19 Prevention and Control and the Joint Prevention and Control Mechanism of the State Council was invited as a distinguished guest to attend the meeting for guidance. Institutions from China's vaccine research and development, production, supervision and application fields, including government departments, scientific research institutes, universities, production enterprises and other 27 governing bodies, a total of more than 60 people attended the meeting on site and remotely.


Yang Xiaoming, chairman of the Vaccine Alliance and chairman of China National Biotec Company Group, delivered an opening remarks on behalf of the Alliance. He pointed out that with the outbreak and prevalence of COVID-19 infection, global public health safety is facing severe challenges and tests. Rapid emergency response and successful development of vaccines have become urgent tasks at present and in the future. Vaccines are the most economical and effective means to prevent and control infectious diseases, and are also important means to carry out biological safety protection and safeguard national security. At present, the prevention and control of the epidemic situation has changed from an emergency state to normalization. The current primary task is to fully protect people's lives, health and safety and fully restore social and economic order. Vaccines are the fundamental measure to accomplish this task. China is one of the few countries in the world that can rely on its own capabilities to solve the problem of immunization supply and vaccination. At present, China can cope with most infectious diseases that are harmful to the population and highly infectious. A vaccine application research and industrial development system was also built up a preliminary form, but there is still a certain gap from the target. Today, the number of governing units of the Vaccine Alliance has increased from 14 to 27, which is the mainstay of the development of China's vaccine industry. At this critical moment in the global fight against the epidemic, he suggests experts attending the meeting to actively offer suggestions and advices on how to achieve the ultimate goal of epidemic prevention and control, complete the task and mission of China's vaccine industry, and jointly fight the epidemic with global counterparts, produce vaccine as early as possible and as good as possible, guarantee supply and promote application and R&D, strengthen the development of China's vaccine industry and promote international cooperation against the epidemic.


Sun Yanrong, Deputy Director of the China National Center for Biotechnology Development of the Ministry of Science and Technology, said in her speech that science and technology are the most powerful weapon to overcome the COVID-19 epidemic. It can provide strong support to return life to normal. She talked about her feelings with several words featured by"100". First, in the past 100 years, China's vaccine products industry has gone through a 100-year development process. People have changed from passive immunization to active immunization, achieving a substantial increase in life expectancy. The second is 100 days. In the more than 100 days since the outbreak of the epidemic, more than a dozen scientific research teams in China have gone all out to develop vaccines day and night, not only fast but also good. It is precisely because of their efforts that we have made, five research and development teams' vaccines have entered the clinical trial stage today. Third are 100 people. In this scientific research, our country has laid out 5 vaccine research and development technical routes and 12 research and development teams. In addition, we still have 100 backbone personnel and 100 technicians working hard, which shows us the hope of getting out of the strait and overcoming the epidemic. Fourth are 100 projects. At present, more than 100 products are being developed around the world. We have seen the joint efforts of scientists around the world and the selfless dedication of entrepreneurs, contributing to the global war against epidemic. The fifth is score 100. I believe that the accumulation and precipitation of our vaccine industry over the past 100 years can really make new contributions to the development of safe and effective vaccines, prevent and control global epidemics, and protect of the life and health of all mankind.


In his speech, Director Wu Zhiyin of the Vaccine research and development committee for COVID-19 Prevention and Control and the Joint Prevention and Control Mechanism of the State Council pointed out that vaccines are the "ballast stones" for the global fight against the new crown epidemic. At present, important progress has been made in the research and development of the COVID-19 vaccine. He thanked all scientific research teams for their efforts in the research and development of the COVID-19 vaccine. However, vaccine research and development cannot be slackened at all. All scientific research teams should improve their strategic layout, focus on the future, work together, accelerate research and development, and strive for the early marketing of the COVID-19 vaccine.


Zhang Yuntao, vice president of China National Biotec Company Group, introduced the establishment of the vaccine alliance, its tasks and responsibilities, systematically introduced the research and development progress of the COVID-19 vaccine at home and abroad, and made a forecast and judgment on the future development of COVID-19 vaccine.


At the scene, Dr. Anita Zaidi, Director of the Vaccine Development Team of the Bill and Melinda Gates Foundation, Dr. David Kaslow, Vice President of Essential Drugs and Head of Vaccine Innovation and Accessibility Center of PATH, Dr. Philip Minor, former deputy director of the British National Institute for Biological Products Control (NIBSC), and Dr. Seth Berkley, president of the Global Alliance for Vaccines and Immunization (GAVI), also sent videos to the conference to affirm China's performance and contribution in the prevention and control of the epidemic.


Dr. Anita Zaidi, Director of Vaccine Development Department of Gates Foundation, said that he was glad to see China's great efforts and investment in the research and development of the COVID-19 vaccine. Chinese researchers have established various vaccine development pipelines, which reflects the firm commitment of China's public and private sectors to jointly cope with this huge global challenge. Dr. Anita Zaidi pointed out that the Gates Foundation will support Chinese partners in meeting the challenges of the pandemic and will jointly develop and deploy vaccines, drugs and diagnostic reagents to help the world.


David Kaslow, vice president of PATH, expressed great pleasure at the establishment of the China Vaccine Innovation Alliance and affirmed the progress of China's vaccine research and development and production capacity and its contribution to global health. He said that during his work with China's vaccine partners, PATH continues to see the great potential released by China's innovative forces. China has developed of more than 50 COVID-19 vaccines candidates, some of which are advanced at an unprecedented speed. It is hoped that Chinese vaccine companies will continue to make important contributions to the global supply of safe and effective vaccines.


Dr. Philip Minor, former deputy director of NIBSC, believes that China has strong scientific research capability and strong vaccine production capacity, and has developed a large number of vaccines suitable for special purposes in the country, such as hepatitis vaccine and EV71. These capabilities can be well applied to the development of COVID-19 vaccines.


Dr. Seth Berkley, President of GAVI, first expressed warm congratulations on China's success in containing the epidemic. He pointed out that the world is now facing the biggest public health crisis in 100 years, and the greatest hope to resolve this crisis is to develop vaccines. International cooperation will be the key to fighting the epidemic. The initiatives and innovations of the China Vaccine Alliance can make great contributions to global health and safety. GAVI looks forward to continuing to cooperate with Chinese manufacturers.


On behalf of China's Strategic Alliance for Technological Innovation in the Vaccine Industry, Zhang Yuntao read out a proposal to all colleagues in the vaccine industry. The proposal emphasizes that in the face of the complicated situation of the COVID-19 epidemic, vaccine enterprises should further play their role in fighting the epidemic, better fulfill their social responsibilities, jointly promote scientific and technological research on vaccines, ensure vaccine research and development, ensure the safety of vaccine application, and fully utilize the important role of vaccines in safeguarding public health and national security. To strengthen the construction of the whole vaccine industry chain, improve the overall level and ability of the vaccine industry to serve the society; We will promote international cooperation in vaccine research and development, join hands in the global fight against the epidemic, demonstrate the responsibility of major countries, jointly build a "human health community" with the people of the world, and join hands with other countries to deal with and defeat the global epidemic as soon as possible.


Academician Wang Junzhi of National Institution for Food and Drug Control and Chief Scientist of NIBSC Dr.Javier Martin made keynote speeches on research and development of the COVID-19 vaccine. After that, the participants discussed how to explore the full potential of the vaccine alliance. Finally, Yang Xiaoming summarized the discussion and said that in the future, he would further focus on the alliance's tasks and highlight the role of vaccines.


Attached is the governing unit of the Vaccine Alliance:

1, China National Biotec Company Group.

2, Advaccine ( Suzhou )Biotechnology Co 

3, Beijing Aimei Biological Vaccine Technology Group Co., Ltd.

4, Sinovac Biotech Co.,Ltd. 

5, Beijing Minhai Biotechnology Co., Ltd

6, Chongqing Zhifei Biological Products Co., Ltd

7, Fudan University

8, Guangxi Center for Disease Prevention and Control

9, He Nan Center for Disease Prevention and Control

10, Hualan Biological Engineering, Inc.

11, Jiang Su Center for Disease Prevention and Control

12, Institute of Bioengineering, Military Medical Research Institute

13, CanSino Biologics Inc.

14, Tsinghua University 15, Xiamen University 16, Stemirna Therapeutics Co., Ltd. 17, Sichuan University 18, Suzhou Abogen  Biotechnology Co., Ltd. 19, Walvax Biotechnology Co., Ltd.20, Changchun Bcht Biotechnology Co.21, Institute of Virus Disease Prevention and Control of China Center for Disease Control and Prevention 22,National Institute for Communicable Disease Control and Prevention Chinese Center for Disease Control and Prevention23,National Immunization Program Chinese Center for Disease Control and Prevention

24, Institut Pasteur of Shanghai Chinese Academy of Sciences

25, National Institutes for Food and Drug Control

26, Institute of Medical Biology Chinese Academy of Medical Sciences

27, Zhuhai Lifanda Biotechnology Co., Ltd. 


In order to accelerate vaccine research and development in China, promote the upgrading of key industrial technologies and the quality of vaccine products, strengthen the technological reserve of China's vaccine industry, improve the ability to deal with new and emergency epidemic outbreaks and abilities of disease prevention and control, and promote the healthy development of the vaccine industry, with the promotion and support of the Ministry of Science and Technology, China National Biotec Company Group, as the supporting unit of the alliance, led the establishment of a strategic alliance for Chinese vaccine industry technology innovation strategic alliance in 2013.

腾讯麻将游戏 全网发行的股票 霸王龙捕鱼 未来云南麻将官方网站 填大坑棋牌怎么玩 8开头的股票是什么 有没有赚钱的网游 qq打麻将在qq上怎么打开 fg美人捕鱼下载 山东十一运夺金走势图新浪 彩金捕鱼送话费下载